bullish
Oneness Biotech (4743 TT): Worth of Attention Ahead of Upcoming Key Milestones
374 Views19 Mar 2022 18:15
SUMMARY
- Oneness Biotech (4743 TT)'s approved drug in Taiwan, Fespixon is the world’s first drug to treat diabetic foot ulcers with superiority in complete wound closure to the standard of care.
- Fespixon is under review in China, and is under multiple NDA submissions to Asian health authorities. The U.S. phase 3 study is expected to be completed in H1 2023.
- Key milestones are expected from two other late-stage pipeline drug candidates, FB825 and FB704A in 2022 and beyond.
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Rising
Tina Banerjee
Global Healthcare Analyst
Price Chart(Sign Up to Access)
- Oneness Biotech (4743 TT): Marketing Progress of Fespixon in China Opens a New Revenue Stream23 Jul 2024
- Oneness Biotech (4743 TT): Global Expansion of Marketed Product & Pipeline Progress14 May 2023
- Oneness Biotech (4743 TT): Positive Clinical Trial Progress Is Pushing Stock Prices to Higher Highs30 Aug 2022
x